ALNY · Company research
Alnylam Pharmaceuticals, Inc. (ALNY): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
33records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals (ALNY) vs. IONS and ARWR: Can Pipeline Growth Restore Confidence After the Guidance Cut? - Yahoo Finance | Alnylam Pharmaceuticals (ALNY) vs. IONS and ARWR: Can Pipeline Growth Restore Confidence After the Guidance Cut? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 14, 2026 | neutral | 0 | 0.6 |
| If You Invested $1000 In Alnylam Pharmaceuticals Stock 15 Years Ago, You Would Have This Much Today - Benzinga | If You Invested $1000 In Alnylam Pharmaceuticals Stock 15 Years Ago, You Would Have This Much Today Benzinga | View source ↗ | Benzinga | Oct 13, 2026 | neutral | 0 | 0.6 |
| Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why | Prime Medicine (PRME) has achieved significant regulatory and clinical progress, receiving FDA clearance for PM647 targeting alpha-1 antitrypsin deficiency and dosing the first patient in a phase I/II trial of PM577a for Wilson disease. The stock has gained 26% over the past month, outperforming the biotech industry's 2.8% decline, driven by these encouraging developments in its Prime Editing platform for genetic disease treatments. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | bullish | 0.4 | 1 |
| PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know | PMV Pharmaceuticals (PMVP) has gained nearly 19% in three months following encouraging clinical data for its lead drug rezatapopt, which achieved a 46% response rate in ovarian cancer patients. The company plans to submit an NDA in Q1 2027 and raised $50.8 million through a public offering to fund operations into Q1 2028. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | bullish | 0.4 | 1 |
| argenx Meets Primary Endpoint in Phase II Celiac Disease Study | argenx announced positive phase II results for FB102, an investigational therapy for celiac disease, meeting its primary endpoint with significant improvements in intestinal tissue measures versus placebo and no new safety signals. The company plans to advance FB102 into late-stage development and evaluate it for other autoimmune conditions. However, the stock declined nearly 12% following a separate announcement that argenx discontinued its phase III UNITY study for Vyvgart Hytrulo in Sjögren's disease. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | neutral | 0 | 1 |
| EDIT Set to Begin First-in-Human Study in Hypercholesterolemia | Editas Medicine announced approval to initiate the Strive phase I/II clinical study of EDIT-401, an investigational in vivo gene-editing therapy for heterozygous familial hypercholesterolemia (HeFH) in Australia. The single-dose therapy demonstrated approximately 90% or greater reductions in atherogenic lipoproteins in preclinical primate studies. Patient dosing is planned for 2026 with initial safety data expected in Q1 2027. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 0.25 | 1 |
| EDIT Set to Begin First-in-Human Study in Hypercholesterolemia | Editas Medicine announced approval to initiate the Strive phase I/II clinical study of EDIT-401, an investigational in vivo gene-editing therapy for heterozygous familial hypercholesterolemia (HeFH) in Australia. The single-dose therapy demonstrated approximately 90% or greater reductions in atherogenic lipoproteins in preclinical primate studies. Patient dosing is planned for 2026 with initial safety data expected in Q1 2027. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 0.25 | 1 |
| Alnylam Pharmaceuticals, Inc. (ALNY) Stock Price, News, Quote & History - Yahoo! Finance Canada | Alnylam Pharmaceuticals, Inc. (ALNY) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 8, 2026 | neutral | 0 | 0.6 |
| Here's Why You Should Add LPCN Stock to Your Portfolio Now | Lipocine (LPCN) is an emerging specialty pharmaceutical company with an approved oral testosterone replacement therapy (Tlando) generating royalties and expanding internationally. The company's key near-term catalyst is Brlizio (LPCN 1154), an oral brexanolone treatment for postpartum depression entering phase III BLOOM study in late 2026. LPCN carries a Zacks Rank #2 (Buy) with a broader pipeline targeting depression, obesity, epilepsy, and liver cirrhosis. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | neutral | 0 | 1 |
| Here's Why You Should Add LPCN Stock to Your Portfolio Now | Lipocine (LPCN) is an emerging specialty pharmaceutical company with an approved oral testosterone replacement therapy (Tlando) generating royalties and expanding internationally. The company's key near-term catalyst is Brlizio (LPCN 1154), an oral brexanolone treatment for postpartum depression entering phase III BLOOM study in late 2026. LPCN carries a Zacks Rank #2 (Buy) with a broader pipeline targeting depression, obesity, epilepsy, and liver cirrhosis. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | neutral | 0 | 1 |
| Here's Why You Should Add LPCN Stock to Your Portfolio Now | Lipocine (LPCN) is an emerging specialty pharmaceutical company with an approved oral testosterone replacement therapy (Tlando) generating royalties and expanding internationally. The company's key near-term catalyst is Brlizio (LPCN 1154), an oral brexanolone treatment for postpartum depression entering phase III BLOOM study in late 2026. LPCN carries a Zacks Rank #2 (Buy) with a broader pipeline targeting depression, obesity, epilepsy, and liver cirrhosis. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | neutral | 0 | 1 |
| Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash | Ultragenyx Pharmaceutical has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million following FDA approval of its gene therapy Genglycos. After a $42 million NIH payment obligation, approximately $168 million in non-dilutive capital will support the company's research, development, and commercialization efforts, helping it move toward profitability without equity financing. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.25 | 1 |
| Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash | Ultragenyx Pharmaceutical has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million following FDA approval of its gene therapy Genglycos. After a $42 million NIH payment obligation, approximately $168 million in non-dilutive capital will support the company's research, development, and commercialization efforts, helping it move toward profitability without equity financing. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.25 | 1 |
| Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash | Ultragenyx Pharmaceutical has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million following FDA approval of its gene therapy Genglycos. After a $42 million NIH payment obligation, approximately $168 million in non-dilutive capital will support the company's research, development, and commercialization efforts, helping it move toward profitability without equity financing. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.25 | 1 |
| Alnylam Pharmaceuticals Inc (ALNY) Stock Price, Trades & News - GuruFocus | Alnylam Pharmaceuticals Inc (ALNY) Stock Price, Trades & News GuruFocus | View source ↗ | GuruFocus | Oct 7, 2026 | neutral | 0 | 0.6 |
| ETON Stock Surges 108% in Six Months: Here's What You Need to Know | Eton Pharmaceuticals has gained 108% over six months, driven by 99% Q2 product sales growth and successful Hemangeol relaunch. The company raised 2026 revenue guidance to above $145 million with 35%+ adjusted EBITDA margins. Pipeline expansion including new launches and late-stage candidates like ASN-001 provide additional growth opportunities. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 0.25 | 1 |
| PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal | Pacira BioSciences announced an exclusive agreement with Italian pharmaceutical company Molteni Farmaceutici to distribute and commercialize Exparel across the EU and UK. Molteni will launch the long-acting local anesthetic in Italy, Germany, Austria, and Poland starting in 2027, while Pacira retains manufacturing rights and will receive upfront payments, supply fees, and royalties. The deal supports Pacira's international expansion strategy while the company advances other pain management products including Zilretta and PCRX-201. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.25 | 1 |
| PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal | Pacira BioSciences announced an exclusive agreement with Italian pharmaceutical company Molteni Farmaceutici to distribute and commercialize Exparel across the EU and UK. Molteni will launch the long-acting local anesthetic in Italy, Germany, Austria, and Poland starting in 2027, while Pacira retains manufacturing rights and will receive upfront payments, supply fees, and royalties. The deal supports Pacira's international expansion strategy while the company advances other pain management products including Zilretta and PCRX-201. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.25 | 1 |
| Type 2 Diabetes Market to Grow Significantly During the Forecast Period (2026–2036), with Rising Prevalence and Increasing Uptake of Next-Generation Therapies | DelveInsight | The type 2 diabetes market is projected to experience steady growth through 2036, driven by rising global prevalence, obesity, and adoption of next-generation therapies including GLP-1 receptor agonists and SGLT2 inhibitors. Key emerging drugs from major pharmaceutical companies like Novo Nordisk, Eli Lilly, and Boehringer Ingelheim are expected to reshape the market landscape with improved glycemic control and weight management benefits. | View source ↗ | GlobeNewswire Inc. | Oct 5, 2026 | bullish | 1 | 1 |
| Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm | Alnylam Pharmaceuticals faces a securities fraud investigation following a significant stock price decline. On July 30, 2026, the company lowered its TTR product sales guidance by approximately $200 million due to slower-than-expected market adoption in the ATTR-CM market after initial pent-up demand was satisfied. The announcement triggered a 28.31% stock price drop, prompting a class action investigation by Glancy Prongay Wolke & Rotter LLP on behalf of affected shareholders. | View source ↗ | GlobeNewswire Inc. | Oct 5, 2026 | bearish | -1 | 1 |
| Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz | The Law Offices of Frank R. Cruz is investigating Alnylam Pharmaceuticals for potential federal securities law violations. On July 30, 2026, Alnylam lowered its full-year 2026 TTR product sales guidance by approximately $200 million due to slower-than-expected growth in the ATTR-CM market after initial pent-up demand was satisfied. The announcement triggered a sharp 28.31% stock price decline, causing investor losses. | View source ↗ | GlobeNewswire Inc. | Oct 2, 2026 | bearish | -1 | 1 |
| Alnylam Pharmaceuticals (ALNY) Stock Looks Above Fair Value As Shares Fell 49% - Simply Wall Street | Alnylam Pharmaceuticals (ALNY) Stock Looks Above Fair Value As Shares Fell 49% Simply Wall Street | View source ↗ | Simply Wall Street | Oct 2, 2026 | neutral | 0 | 0.6 |
| Alnylam Shares Fall as Investors Weigh Earlier 2026 Outlook Reset Against a Near-Term Data Wait - Quiver Quantitative | Alnylam Shares Fall as Investors Weigh Earlier 2026 Outlook Reset Against a Near-Term Data Wait Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 1, 2026 | neutral | 0 | 0.6 |
| A former football player’s symptoms were attributed to football or aging. His heart diagnosis came late. - Stock Titan | A former football player’s symptoms were attributed to football or aging. His heart diagnosis came late. Stock Titan | View source ↗ | Stock Titan | Sep 29, 2026 | neutral | 0 | 0.6 |
| Alnylam Needs Stronger AMVUTTRA Execution To Justify More Upside (NASDAQ:ALNY) - Seeking Alpha | Alnylam Needs Stronger AMVUTTRA Execution To Justify More Upside (NASDAQ:ALNY) Seeking Alpha | View source ↗ | Seeking Alpha | Sep 26, 2026 | neutral | 0 | 0.6 |
| Vutrisiran cut the risk of decline by 52% in Alnylam's heart amyloidosis analysis - Stock Titan | Vutrisiran cut the risk of decline by 52% in Alnylam's heart amyloidosis analysis Stock Titan | View source ↗ | Stock Titan | Aug 30, 2026 | neutral | 0 | 0.6 |
| Alnylam Pharmaceuticals (ALNY) Stock Looks Cheap After A 47% Fall Yet Rich On Earnings - Yahoo Finance | Alnylam Pharmaceuticals (ALNY) Stock Looks Cheap After A 47% Fall Yet Rich On Earnings Yahoo Finance | View source ↗ | Yahoo Finance | Aug 24, 2026 | neutral | 0 | 0.6 |
| Alnylam (ALNY) Stock May Look Rich On Earnings Despite Weaker Price Action - Simply Wall Street | Alnylam (ALNY) Stock May Look Rich On Earnings Despite Weaker Price Action Simply Wall Street | View source ↗ | Simply Wall Street | Aug 24, 2026 | neutral | 0 | 0.6 |
| Why Alnylam Pharmaceuticals (ALNY) Stock Is Up Today - Quiver Quantitative | Why Alnylam Pharmaceuticals (ALNY) Stock Is Up Today Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 19, 2026 | neutral | 0 | 0.6 |
| Alnylam Pharmaceuticals Stock: 5 Straight Red Days, Down 14% - Trefis | Alnylam Pharmaceuticals Stock: 5 Straight Red Days, Down 14% Trefis | View source ↗ | Trefis | Jul 16, 2026 | neutral | 0 | 0.6 |
| Alnylam Pharmaceuticals Stock In Shambles: Down 14% With 5-Day Losing Streak - Trefis | Alnylam Pharmaceuticals Stock In Shambles: Down 14% With 5-Day Losing Streak Trefis | View source ↗ | Trefis | Jul 16, 2026 | neutral | 0 | 0.6 |
| Alnylam Pharmaceuticals (NASDAQ:ALNY) Shows Accelerating Momentum as a High Growth Stock - ChartMill | Alnylam Pharmaceuticals (NASDAQ:ALNY) Shows Accelerating Momentum as a High Growth Stock ChartMill | View source ↗ | ChartMill | Jul 14, 2026 | neutral | 0 | 0.6 |
| ALNY Forecast — Price Target — Prediction for 2027 - TradingView | ALNY Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.